FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Scott Wadler

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Anatomy

Tumor Cells, Cultured

Co-author Network

Publications

TOP 3
Shivaani Kummar; Shwu-Huey Liu; Mark O'Rourke; Michal Rose; Joe Stephenson; Tahmun Su; Robert Tilton; Scott Wadler; Wayne Brenckman; Yung-Chi Cheng; M Sitki Copur; Zaoli Jiang; Edward Chu
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Anna C Pavlick; Jennifer Wu; John Roberts; Mark A Rosenthal; Anne Hamilton; Scott Wadler; Kathleen Farrell; Michelle Carr; David Fry; Anthony J Murgo; Ruth Oratz; Howard Hochster; Leonard Liebes; Franco Muggia
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.
Leonard B Saltz; Heinz-Josef Lenz; Hedy L Kindler; Howard Hochster; Scott Wadler; Paulo M Hoff; Nancy Kemeny; Ellen M Hollywood; Mithat Gonen; Marcus Quinones; Meroe Morse; Helen X Chen
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Scott Wadler (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Shivaani Kummar; Shwu-Huey Liu; Mark O'Rourke; Michal Rose; Joe Stephenson; Tahmun Su; Robert Tilton; Scott Wadler; Wayne Brenckman; Yung-Chi Cheng; M Sitki Copur; Zaoli Jiang; Edward Chu
A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Clinical colorectal cancer 2011;10(2):85-96.
2009: Anna C Pavlick; Jennifer Wu; John Roberts; Mark A Rosenthal; Anne Hamilton; Scott Wadler; Kathleen Farrell; Michelle Carr; David Fry; Anthony J Murgo; Ruth Oratz; Howard Hochster; Leonard Liebes; Franco Muggia
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.
Cancer chemotherapy and pharmacology 2009;64(4):803-10.
2007: Leonard B Saltz; Heinz-Josef Lenz; Hedy L Kindler; Howard Hochster; Scott Wadler; Paulo M Hoff; Nancy Kemeny; Ellen M Hollywood; Mithat Gonen; Marcus Quinones; Meroe Morse; Helen X Chen
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4557-61.
2007: Mark Einstein; Anna S Kadish; Robert D Burk; Mimi Y Kim; Scott Wadler; Howard Streicher; Gary L Goldberg; Carolyn D Runowicz
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.
Gynecologic oncology 2007;106(3):453-60.
2007: Scott Wadler
Molecular targeting in pancreatic cancer.
Reviews on recent clinical trials 2007;2(1):69-75.
2007: Scott Wadler
Targeted therapy in colorectal cancer.
Clinical colorectal cancer 2007;6(5):357-61.
2007: Jonathan J Beitler; Richard V Smith; Randall P Owen; Carl E Silver; Madhu Mazumdar; Scott Wadler
Phase II clinical trial of parenteral hydroxyurea and hyper-fractionated, accelerated external beam radiation therapy in patients with advanced squamous cell carcinoma of the head and neck: toxicity and efficacy with continuous ribonucleoside reductase inhibition.
Head & neck 2007;29(1):18-25.
2006: David P Ryan; Donna Niedzwiecki; Donna Hollis; Brent E Mediema; Scott Wadler; Joel E Tepper; Richard M Goldberg; Robert J Mayer
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(16):2557-62.
2006: SANJAY GOEL; Kavita Desai; Manuel Macapinlac; Scott Wadler; Gary L Goldberg; Abbie Fields; Mark Einstein; Fabio Volterra; Benny Wong; Russell Martin; Sridhar Mani
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.
Investigational new drugs 2006;24(2):125-34.
2006: Howard Hochster; Elizabeth R Plimack; John Mandeli; Scott Wadler; Carolyn D Runowicz; Gary L Goldberg; James Speyer; Robert C Wallach; Franco Muggia
Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study.
Gynecologic oncology 2006;100(2):324-9.
2006: D Yi-Shin Kuo; Patrick Timmins; Stephanie V Blank; Abbie L Fields; Gary L Goldberg; Anthony J Murgo; Paul J Christos; Scott Wadler; Carolyn D Runowicz
Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium.
Gynecologic oncology 2006;100(1):160-5.
2005: Scott Wadler; Howard Kaufman; Marshall Horwitz; Stephen Morley; David Kirn; Robert Brown; Stan Kaye; David S Soutar
The dl1520 virus is found preferentially in tumor tissue after direct intratumoral injection in oral carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(7):2781-2; author reply 2782.
2005: ROBERT G MAKI; Andrew Kraft; Kelly Scheu; Jennifer Yamada; Scott Wadler; Cristina R Antonescu; John J Wright; Gary K Schwartz
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Cancer 2005;103(7):1431-8.
2005: Scott Wadler
Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?
Cancer 2005;103(1):1-4.
2004: Al B Benson; Jaffer A Ajani; Robert B Catalano; Constance Engelking; Steven M Kornblau; James A Martenson; Richard McCallum; Edith P Mitchell; Thomas M O'Dorisio; Everett E Vokes; Scott Wadler
Recommended guidelines for the treatment of cancer treatment-induced diarrhea.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(14):2918-26.
2004: Richard V Smith; S Yedida Goldman; Jonathan J Beitler; Scott Wadler
Decreased short- and long-term swallowing problems with altered radiotherapy dosing used in an organ-sparing protocol for advanced pharyngeal carcinoma.
Archives of otolaryngology--head & neck surgery 2004;130(7):831-6.
2004: Scott Wadler; Della Makower; Caroline Clairmont; Paula Lambert; Karen Fehn; Mario Sznol
Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(9):1553-63.
2004: Farr Nezhat; Scott Wadler; Franco Muggia; John Mandeli; Gary L Goldberg; Jamal Rahaman; Carolyn D Runowicz; Anthony J Murgo; Ginger J Gardner
Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Gynecologic oncology 2004;93(1):144-8.
2004: Andreas Kaubisch; Ronald Kaleya; Hilda Haynes; Alla Rozenblit; Scott Wadler
Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors.
Cancer chemotherapy and pharmacology 2004;53(4):337-40.
2004: Scott Wadler; Donna Levy; Helen L Frederickson; Carla I Falkson; Yuexian Wang; Edie Weller; Robert D Burk; Gloria Y F Ho; Anna S Kadish
A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.
Gynecologic oncology 2004;92(3):957-64.
2004: Howard Hochster; Elizabeth R Plimack; Carolyn D Runowicz; James Speyer; Robert C Wallach; Joan Sorich; John Mandeli; Scott Wadler; John Wright; Franco M Muggia
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(1):120-6.
2003: SANJAY GOEL; A Bulgaru; Howard Hochster; Scott Wadler; William C Zamboni; Merrill J Egorin; Percy Ivy; L Leibes; Franco Muggia; Graham Lockwood; E Harvey; G Renshaw; Sridhar Mani
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(11):1682-7.
2003: George A Omura; Mark F Brady; Katherine Y Look; Hervy E Averette; James E Delmore; Harry J Long; Scott Wadler; Gregory Spiegel; Arbuck Susan
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: an intergroup study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(15):2843-8.
2003: Scott Wadler; Donna E Levy; Sarah T Lincoln; Gamini S Soori; Julian C Schink; Gary L Goldberg
Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2110-4.
2003: Oday Hamid; Mary Varterasian; Scott Wadler; J Randolph Hecht; Al Benson; Evanthia Galanis; Margaret Uprichard; Charles Omer; Paul Bycott; Robert C Hackman; Anthony F Shields
Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1498-504.
2003: Della Makower; Joseph A Sparano; Scott Wadler; Karen Fehn; Leon Landau; Paul Wissel; Melissa Versola; Sridhar Mani
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
Cancer investigation 2003;21(2):177-84.
2003: Mace L Rothenberg; Ping-Yu Liu; Patricia S Braly; Sharon P Wilczynski; Edward V Hannigan; Scott Wadler; Gavin Stuart; Caroline Jiang; Maurie Markman; David S Alberts
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1313-9.
2003: SANJAY GOEL; Scott Wadler; Anthony Hoffman; Fabio Volterra; Cheryl Baker; Elliot Nazario; Percy Ivy; Alyson Silverman; Sridhar Mani
A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer.
Investigational new drugs 2003;21(1):103-7.
2003: Della Makower; Alla Rozenblit; Howard Kaufman; Morris Edelman; Maureen E Lane; James Zwiebel; Hilda Haynes; Scott Wadler
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):693-702.
2003: Scott Wadler; Bo Yu; Jian-You Tan; Ronald Kaleya; Alla Rozenblit; Della Makower; Morris Edelman; Maureen Lane; Elizabath Hyjek; Marshall Horwitz
Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):33-43.
2002: Scott Wadler; Della Makower; Bo Yu; Jian-You Tan; Alla Rozenblit; Howard Kaufman; Morris Edelman; Maureen E Lane; James Zwiebel
Clinical applications of p53-directed gene therapy.
I supplementi di Tumori : official journal of Società italiana di cancerologia ... [et al.] 2002;1(6):S21.
2002: Huda S Salman; Jacob Cynamon; Marcy B Jagust; Curtis W Bakal; Alla Rozenblit; Ronald Kaleya; Abdissa Negassa; Scott Wadler
Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
Clinical colorectal cancer 2002;2(3):173-9.
2002: SANJAY GOEL; Minaxi Jhawer; Lakshmi Rajdev; Una Hopkins; Karen Fehn; Cheryl Baker; Hoo G Chun; Della Makower; Leon Landau; Anthony Hoffman; Scott Wadler; Sridhar Mani
Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies.
American journal of clinical oncology 2002;25(5):528-34.
2002: Bo Yu; Maureen E Lane; Scott Wadler
SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells.
Biochemical pharmacology 2002;64(7):1091-100.
2002: Franco M Muggia; Leonard Liebes; Maitreyee Hazarika; Scott Wadler; Anne Hamilton; Gila Hornreich; Joan Sorich; Chung Chiang; Elliot Newman; Milan Potmesil; Howard Hochster
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 days.
Anti-cancer drugs 2002;13(8):819-25.
2002: Randall P Owen; Thanjavur S Ravikumar; Carl E Silver; Jonathan J Beitler; Scott Wadler; Jacqueline A Bello
Radiofrequency ablation of head and neck tumors: dramatic results from application of a new technology.
Head & neck 2002;24(8):754-8.
2002: Howard H Bailey; Donna Levy; Linda S Harris; Julian C Schink; Francine Foss; Peter Beatty; Scott Wadler
A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.
Gynecologic oncology 2002;85(3):464-8.
2002: Scott Wadler; Carlos Brain; Paul J Catalano; Avi I Einzig; David Cella; Al B Benson
Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study E6296.
Cancer journal (Sudbury, Mass.) 2002;8(3):282-6.
2002: Jonathan J Beitler; Patrick Anderson; Hilda Haynes; Brij M Sood; Abbie Fields; Gary L Goldberg; Bhadrasain Vikram; Carolyn D Runowicz; Scott Wadler
Phase I clinical trial of parenteral hydroxyurea in combination with pelvic and para-aortic external radiation and brachytherapy for patients with advanced squamous cell cancer of the uterine cervix.
International journal of radiation oncology, biology, physics 2002;52(3):637-42.
2001: Sandeep Soni; Eva Radel; Richard V Smith; Morris Edelman; R Sattenberg; Scott Wadler; Jonathan J Beitler
Stage 4 squamous cell carcinoma of the tongue in a child: complete response to chemoradiotherapy.
Journal of pediatric hematology/oncology 2001;23(9):612-5.
2001: Ummekalsoom Malik; Della Makower; Scott Wadler
Interferon-mediated fatigue.
Cancer 2001;92(6 Suppl):1664-8.
2001: Mace L Rothenberg; N J Meropol; E A Poplin; E Van Cutsem; Scott Wadler
Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18):3801-7.
2001: Diego Arango; Georgia A Corner; Scott Wadler; Paul J Catalano; Leonard H Augenlicht
c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo.
Cancer research 2001;61(12):4910-5.
2001: Ari D Fishman; Scott Wadler
Advances in the treatment of metastatic colorectal cancer.
Clinical colorectal cancer 2001;1(1):20-35.
2001: Julian C Schink; E Weller; Linda S Harris; David Cella; J Gerstner; C Falkson; Scott Wadler
Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).
Cancer journal (Sudbury, Mass.) 2001;7(2):155-64.
2001: Lakshmi Rajdev; Z F Yu; Scott Wadler; E Weller; S B Kahn; D Tormey; R Skeel; P H Wiernik
N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial.
Investigational new drugs 2001;19(3):233-7.
2000: B Yu; M E Lane; R G Pestell; C Albanese; Scott Wadler
Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.
Molecular cell biology research communications : MCBRC 2000;3(6):352-9.
2000: Richard V Smith; T Kotz; Jonathan J Beitler; Scott Wadler
Long-term swallowing problems after organ preservation therapy with concomitant radiation therapy and intravenous hydroxyurea: initial results.
Archives of otolaryngology--head & neck surgery 2000;126(3):384-9.
1999: Della Makower; Scott Wadler
Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer.
Seminars in oncology 1999;26(6):663-71.
1999: Howard Hochster; Scott Wadler; Carolyn D Runowicz; Leonard Liebes; H Cohen; Robert C Wallach; Joan Sorich; Beth Taubes; James Speyer
Activity and pharmacodynamics of 21-Day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2553-61.
1999: S Damle; Jonathan J Beitler; Hilda Haynes; M Camacho; E Wolf; Scott Wadler
Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
American journal of clinical oncology 1999;22(4):391-5.
1999: Scott Wadler; S Damle; Hilda Haynes; Ronald Kaleya; Richard Schechner; Robert Berkenblit; R D Ladner; A Murgo
Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1771-8.
1999: C L Dabon-Almirante; S Damle; Scott Wadler; K Hupart
Related case report: in vivo suppression of thyrotropin by 9-cis retinoic acid.
The cancer journal from Scientific American 1999;5(3):171-3.
1999: Scott Wadler; Edward L Schwartz; P Anderson; Carolyn D Runowicz; L Chuang; G Del Priore; Howard Hochster; Gary L Goldberg; Abbie Fields; G Loewen; Hilda Haynes
Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group.
The cancer journal from Scientific American 1999;5(3):165-70.
1999: T Kotz; Suzanne Abraham; Jonathan J Beitler; Scott Wadler; Richard V Smith
Pharyngeal transport dysfunction consequent to an organ-sparing protocol.
Archives of otolaryngology--head & neck surgery 1999;125(4):410-3.
1999: Howard Hochster; James Speyer; John Mandeli; Carolyn D Runowicz; Scott Wadler; G Berk; Robert C Wallach; James F Holland
A phase II double-blind randomized study of the simultaneous administration of recombinant human interleukin-6 and recombinant human granulocyte colony-stimulating factor following paclitaxel and carboplatin chemotherapy in patients with advanced epithelial ovarian cancer.
Gynecologic oncology 1999;72(3):292-7.
1999: Scott Wadler; H Zhang; M Cammer; XP Hu
Quantification of ribonucleotide reductase expression in wild-type and hydroxyurea-resistant cell lines employing in situ reverse transcriptase polymerase chain reaction and a computerized image analysis system.
Analytical biochemistry 1999;267(1):24-9.
1999: F M McGill; D B Ritter; C S Rickard; Ronald Kaleya; Scott Wadler; Wilma Markus Greston; K A O'Hanlan
Krukenberg tumors: can management be improved?
Gynecologic and obstetric investigation 1999;48(1):61-5.
1998: Ralf Metzger; Kathleen D Danenberg; Cynthia G Leichman; Dennis Salonga; Edward L Schwartz; Scott Wadler; Heinz-Josef Lenz; Susan Groshen; Lawrence Leichman; Peter V Danenberg
High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2371-6.
1998: Scott Wadler; Hilda Haynes; Alla Rozenblit; X Hu; Ronald Kaleya; Peter H Wiernik
Sequential phase II trials of fluorouracil and interferon beta ser with or without sargramostim in patients with advanced colorectal carcinoma.
The cancer journal from Scientific American 1998;4(5):331-7.
1998: Scott Wadler; Al B Benson; Constance Engelking; R Catalano; M Field; Steven M Kornblau; E Mitchell; J Rubin; P Trotta; Everett E Vokes
Recommended guidelines for the treatment of chemotherapy-induced diarrhea.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(9):3169-78.
1998: Abbie Fields; Howard Hochster; Carolyn D Runowicz; James Speyer; Gary L Goldberg; C Cohen; PR Dottino; Scott Wadler; G Berk; H Gretz; John Mandeli; J Holland; L Letvak
PSC833: initial clinical results in refractory ovarian cancer patients.
Current opinion in oncology 1998;10 Suppl 1():S21.
1998: Scott Wadler; M Atkins; D Karp; D Neuberg; Hilda Haynes; Janice P Dutcher
Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
The cancer journal from Scientific American 1998;4(4):261-8.
1998: Scott Wadler; RW Horowitz; H Y Zhang; Edward L Schwartz
Effects of perturbations of pools of deoxyribonucleoside triphosphates on expression of ribonucleotide reductase, a G1/S transition state enzyme, in p53-mutated cells.
Biochemical pharmacology 1998;55(9):1353-60.
1998: Jonathan J Beitler; Richard V Smith; Carl E Silver; A Quish; Shivaji Deore; Eduard Mullokandov; DP Fontenla; Scott Wadler; M K Hayes; Bhadrasain Vikram
Close or positive margins after surgical resection for the head and neck cancer patient: the addition of brachytherapy improves local control.
International journal of radiation oncology, biology, physics 1998;40(2):313-7.
1998: Jonathan J Beitler; Richard V Smith; Hilda Haynes; Carl E Silver; A Quish; T Kotz; M Serrano; Allan L Brook; Scott Wadler
A phase I clinical trial of prolonged infusion of hydroxyurea in combination with hyperfractionated, accelerated, external radiation therapy in patients with advanced squamous cell cancer of the head and neck.
Investigational new drugs 1998;16(2):161-9.
1998: Avi I Einzig; P H Wiernik; Scott Wadler; J Kaplan; L T Benson; L Tentoramano; V Tan
Phase I study of paclitaxel (taxol) and granulocyte colony stimulating factor (G-CSF) in patients with unresectable malignancy.
Investigational new drugs 1998;16(1):29-36.
1997: RW Horowitz; H Zhang; Edward L Schwartz; R D Ladner; Scott Wadler
Measurement of deoxyuridine triphosphate and thymidine triphosphate in the extracts of thymidylate synthase-inhibited cells using a modified DNA polymerase assay.
Biochemical pharmacology 1997;54(5):635-8.
1997: Scott Wadler; R Bajaj; D Neuberg; V Agarwal; Hilda Haynes; A B Benson
Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292)
The cancer journal from Scientific American 1997;3(5):284-8.
1997: RW Horowitz; Barbara G Heerdt; X Hu; Edward L Schwartz; Scott Wadler
Combination therapy with 5-fluorouracil and IFN-alpha2a induces a nonrandom increase in DNA fragments of less than 3 megabases in HT29 colon carcinoma cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(8):1317-22.
1997: Della Makower; Scott Wadler; Hilda Haynes; Edward L Schwartz
Interferon induces thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):923-9.
1997: RW Horowitz; Scott Wadler; P H Wiernik
A review of the clinical experience with irinotecan (CPT-11).
American journal of therapeutics 1997;4(5-6):203-10.
1997: Leonard H Augenlicht; Scott Wadler; Georgia A Corner; C Richards; L Ryan; A S Multani; S Pathak; A Benson; D Haller; Barbara G Heerdt
Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial.
Cancer research 1997;57(9):1769-75.
1997: Scott Wadler; Edward L Schwartz; Hilda Haynes; R Rameau; A Quish; John Mandeli; Robert E Gallagher; S Hallam; Abbie Fields; Gary L Goldberg; F McGill; S Jennings; Robert C Wallach; Carolyn D Runowicz
All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group.
Cancer 1997;79(8):1574-80.
1997: Jonathan J Beitler; Patrick S Anderson; Scott Wadler; Carolyn D Runowicz; M K Hayes; Abbie L Fields; Brij M Sood; Gary L Goldberg
Pelvic exenteration for cervix cancer: would additional intraoperative interstitial brachytherapy improve survival?
International journal of radiation oncology, biology, physics 1997;38(1):143-8.
1997: Sandra M Swain; Fredrick S Whaley; M C Gerber; S Weisberg; M York; D Spicer; Stephen E Jones; Scott Wadler; A Desai; Charles L Vogel; James Speyer; A Mittelman; S Reddy; K Pendergrass; E Velez-Garcia; Michael S Ewer; J R Bianchine; Richard Gams
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1318-32.
1997: H Zhang; Scott Wadler
Micropreparation of cultured cells for in situ reverse transcription PCR.
BioTechniques 1997;22(4):618-20, 622, 624.
1997: Scott Wadler; Edward L Schwartz
Role of interferon as a modulator of fluoropyrimidines: reply to a recent editorial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):139-40; discussion 141.
1997: A N Leaf; D Neuberg; Edward L Schwartz; Scott Wadler; P S Ritch; Janice P Dutcher; G L Adams
An ECOG phase II study of amonafide in unresectable or recurrent carcinoma of the head and neck (PB390). Eastern Cooperative Oncology Group.
Investigational new drugs 1997;15(2):165-72.
1996: Joseph A Sparano; S Lipsitz; Scott Wadler; R Hansen; P W Bushunow; J Kirkwood; P J Flynn; Janice P Dutcher; Al B Benson
Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
American journal of clinical oncology 1996;19(6):546-51.
1996: Scott Wadler; Gary L Goldberg; Abbie Fields; P Anderson; Jonathan J Beitler; Brij M Sood; Hilda Haynes; Carolyn D Runowicz
The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.
Seminars in oncology 1996;23(4 Suppl 8):64-8.
1996: Scott Wadler; Hilda Haynes; Jonathan J Beitler; X Hu; S Fell; M Camacho; B Levine; Peter H Wiernik
Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
Cancer 1996;78(1):30-4.
1996: Scott Wadler; B Gleissner; R U Hilgenfeld; Eckhard Thiel; Hilda Haynes; Ronald Kaleya; Alla Rozenblit; Ernst D Kreuser
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
European journal of cancer (Oxford, England : 1990) 1996;32A(7):1254-6.
1996: Abbie L Fields; P S Anderson; Gary L Goldberg; Scott Wadler; Jonathan J Beitler; Brij M Sood; Carolyn D Runowicz
Mature results of a phase II trial of concomitant cisplatin/pelvic radiotherapy for locally advanced squamous cell carcinoma of the cervix.
Gynecologic oncology 1996;61(3):416-22.
1996: Carolyn D Runowicz; John Mandeli; James Speyer; Scott Wadler; Howard Hochster; L Garrison; J F Holland
Phase I/II study of PIXY321 in combination with cyclophosphamide and carboplatin in the treatment of ovarian cancer.
American journal of obstetrics and gynecology 1996;174(4):1151-9; discussion 1159-60.
1996: Scott Wadler; B Yeap; S Vogl; P Carbone
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Cancer 1996;77(4):733-42.
1996: Scott Wadler; Hilda Haynes; Richard Schechner; Alla Rozenblit; Peter H Wiernik
Phase I trial of high-dose infusional hydroxyurea, high-dose infusional 5-fluorouracil and recombinant interferon-alpha-2a in patients with advanced malignancies.
Investigational new drugs 1996;13(4):315-20.
1996: Scott Wadler; R Horowitz; J Rao; X Mao; K Schlesinger; Edward L Schwartz
Interferon augments the cytotoxicity of hydroxyurea without enhancing its activity against the M2 subunit of ribonucleotide reductase: effects in wild-type and resistant human colon cancer cells.
Cancer chemotherapy and pharmacology 1996;38(6):522-8.
1995: Scott Wadler; Robert D Burk; D Neuberg; R Rameau; Carolyn D Runowicz; Gary L Goldberg; F McGill; Ruth Tachezy; R Comis; J Edmonson
Lack of efficacy of interferon-alpha therapy in recurrent, advanced cervical cancer.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1995;15(12):1011-6.
1995: Edward L Schwartz; N Baptiste; S Megati; Scott Wadler; B A Otter
5-Ethoxy-2'-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression.
Cancer research 1995;55(16):3543-50.
1995: Edward L Schwartz; N Baptiste; Scott Wadler; Della Makower
Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil.
The Journal of biological chemistry 1995;270(32):19073-7.
1995: J S Rubin; Scott Wadler; Jonathan J Beitler; Hilda Haynes; Alla Rozenblit; F McGill; Gary L Goldberg; Carolyn D Runowicz
Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma.
The Journal of laryngology and otology 1995;109(8):744-7.
1995: Jonathan J Beitler; Scott Wadler; Hilda Haynes; S Fell; Alla Rozenblit; E Wolf; B A Levine
Phase II trial of chemotherapy, external and intraluminal radiation plus surgery for oesophageal cancer.
Medical oncology (Northwood, London, England) 1995;12(2):115-20.
1995: R Horowitz; Edward L Schwartz; Scott Wadler
Modulation of 5-fluorouracil by interferon: a review of potential cellular targets.
Medical oncology (Northwood, London, England) 1995;12(1):3-8.
1995: Scott Wadler
The role of alpha interferon in the biomodulation of disease: preface.
Medical oncology (Northwood, London, England) 1995;12(1):1-2.
1995: James Speyer; John Mandeli; Howard Hochster; Carolyn D Runowicz; Scott Wadler; Robert C Wallach; C Cohen; D Oette; Joan Sorich; E Demakos
A phase I trial of cyclosphosphamide and carboplatinum combined with interleukin-3 in women with advanced-stage ovarian cancer.
Gynecologic oncology 1995;56(3):387-94.
1995: R Horowitz; Scott Wadler
Modulation of 5-FU/alpha-interferon with high-dose continuous infusion hydroxyurea.
The Journal of infusional chemotherapy 1995;5(4):212-4.
1995: Scott Wadler; Hilda Haynes; Peter H Wiernik
Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(1):222-6.
1994: D J Martinelli; Scott Wadler; Curtis W Bakal; Jacob Cynamon; Alla Rozenblit; Hilda Haynes; Ronald Kaleya; P H Wiernik
Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma.
Cancer 1994;74(6):1706-12.
1994: Jonathan J Beitler; Panna S Mahadevia; Carl E Silver; Scott Wadler; J S Rubin; Jacqueline A Bello; R Mitnick; Bhadrasain Vikram
New barriers to ventricular invasion in paraglottic laryngeal cancer.
Cancer 1994;73(10):2648-52.
1994: Edward L Schwartz; N Baptiste; C J O'Connor; Scott Wadler; B A Otter
Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.
Cancer research 1994;54(6):1472-8.
1994: Scott Wadler; L Tenteromano; L Cazenave; Joseph A Sparano; E S Greenwald; Alla Rozenblit; Ronald Kaleya; P H Wiernik
Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer.
Cancer chemotherapy and pharmacology 1994;34(3):266-9.
1994: Scott Wadler; Edward L Schwartz
Biologic agents as biochemical modulators: pharmacologic basis for the interaction of cytotoxic chemotherapeutic drugs and interferon.
Cancer chemotherapy and pharmacology 1994;35(1):21-30.
1993: Scott Wadler; X Mao; R Bajaj; S Hallam; Edward L Schwartz
N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Molecular pharmacology 1993;44(5):1070-6.
1993: Scott Wadler; Hilda Haynes; Jonathan J Beitler; Gary L Goldberg; J F Holland; Howard Hochster; H Bruckner; John Mandeli; Harriet O Smith; Carolyn D Runowicz
Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy. The New York Gynecologic Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1517-22.
1993: Scott Wadler; Jonathan J Beitler; J S Rubin; Hilda Haynes; F McGill; Alla Rozenblit; Gary L Goldberg; C Cohen; James Speyer; Carolyn D Runowicz
Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1511-6.
1993: Joseph A Sparano; Scott Wadler; Leonard Liebes; N J Robert; Edward L Schwartz; Janice P Dutcher
Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
Cancer research 1993;53(15):3509-12.
1993: Joseph A Sparano; Scott Wadler; R B Diasio; R Zhang; Z Lu; Edward L Schwartz; Avi Einzig; Peter H Wiernik
Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(8):1609-17.
1993: Scott Wadler; S Fell; Hilda Haynes; H J Katz; Alla Rozenblit; Ronald Kaleya; Peter H Wiernik
Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
Cancer 1993;71(5):1726-30.
1992: Scott Wadler
The role of interferons in the treatment of solid tumors.
Cancer 1992;70(4 Suppl):949-58.
1992: Scott Wadler; Edward L Schwartz
Principles in the biomodulation of cytotoxic drugs by interferons.
Seminars in oncology 1992;19(2 Suppl 3):45-8.
1992: Scott Wadler
Antineoplastic activity of the combination of 5-fluorouracil and interferon: preclinical and clinical results.
Seminars in oncology 1992;19(2 Suppl 4):38-40.
1992: Edward L Schwartz; Mark Hoffman; C J O'Connor; Scott Wadler
Stimulation of 5-fluorouracil metabolic activation by interferon-alpha in human colon carcinoma cells.
Biochemical and biophysical research communications 1992;182(3):1232-9.
1991: Scott Wadler; Chia-Ping Huang Yang
Reversal of doxorubicin resistance by hydrophobic, but not hydrophilic, forskolins.
Molecular pharmacology 1991;40(6):960-4.
1991: Scott Wadler; B Lembersky; M Atkins; J Kirkwood; N Petrelli
Phase II trial of fluorouracil and recombinant interferon alfa-2a in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(10):1806-10.
1991: Scott Wadler
The role of immunotherapy in colorectal cancer.
Seminars in oncology 1991;18(1 Suppl 1):27-38.
1990: Joseph A Sparano; Edward L Schwartz; K M Salva; M F Pizzillo; Scott Wadler; Peter H Wiernik
Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer.
American journal of clinical oncology 1990;13(5):374-8.
1990: Scott Wadler; R Wersto; V Weinberg; D Thompson; Edward L Schwartz
Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects.
Cancer research 1990;50(18):5735-9.
1990: Scott Wadler; Edward L Schwartz
Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.
Cancer research 1990;50(12):3473-86.
1990: Scott Wadler; M Goldman; A Lyver; Peter H Wiernik
Phase I trial of 5-fluorouracil and recombinant alpha 2a-interferon in patients with advanced colorectal carcinoma.
Cancer research 1990;50(7):2056-9.
1990: Scott Wadler; Peter H Wiernik
Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma.
Seminars in oncology 1990;17(1 Suppl 1):16-21; discussion 38-41.
1990: F McGill; Akinori Adachi; N Karimi; Scott Wadler; E S Kim; Wilma Markus Greston; G J Kleiner
Abnormal cervical cytology leading to the diagnosis of gastric cancer.
Gynecologic oncology 1990;36(1):101-5.
1989: Scott Wadler; Edward L Schwartz; M Goldman; A Lyver; M Rader; M Zimmerman; L Itri; V Weinberg; Peter H Wiernik
Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1769-75.
1989: Scott Wadler; A Lyver; Peter H Wiernik
Clinical toxicities of the combination of 5-fluorouracil and recombinant interferon alfa-2a: an unusual toxicity profile.
Oncology nursing forum 1989;16(6 Suppl):12-5.
1989: Carolyn D Runowicz; Scott Wadler; L Rodriguez-Rodriguez; P Litwin; M Shaves; K A O'Hanlan; Gary L Goldberg; C T Tomaino; R Byrnes
Concomitant cisplatin and radiotherapy in locally advanced cervical carcinoma.
Gynecologic oncology 1989;34(3):395-401.
1989: Scott Wadler; Merrill J Egorin; E G Zuhowski; L Tortorello; K Salva; Carolyn D Runowicz; Peter H Wiernik
Phase I clinical and pharmacokinetic study of thiotepa administered intraperitoneally in patients with advanced malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(1):132-9.
1988: Scott Wadler; Avi Einzig; Janice P Dutcher; N Ciobanu; L Landau; Peter H Wiernik
Phase II trial of recombinant alpha-2b-interferon and low-dose cyclophosphamide in advanced melanoma and renal cell carcinoma.
American journal of clinical oncology 1988;11(1):55-9.